Overview

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

An open-label, randomized, active control inpatient trial to evaluate the efficacy and tolerability of sublingual dexmedetomidine for the treatment of agitation in inpatients with schizophrenia or bipolar disorder as measured by the Positive and Negative Syndrome Scale - Excited Component (PANSS-EC) and Agitation-Calmness Evaluation Scale (ACES). Lorazepam will serve as the active control.

Phase:

Phase 4

Details

Lead Sponsor:

Temple University

Collaborator:

BioXcel Therapeutics Inc

Treatments:

Dexmedetomidine
Lorazepam